Publication: 4268

Publication: 4268

A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (A-DREAM / Alliance A032101).

DOI

URL

Google Scholar

Citation:: J Clin Oncol vol 24 (16_suppl) TPS5118

Meeting Instance:: ASCO 2024
Year:: 2024
Type:: Abstract
Sub type:: Poster General
Funding:: NCTN
Endpoint:: No-Endpoint
Analysis:: Trial-Description-Only
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epreprint

Note:: A-DREAM

Methodological:: No
Biospecimen:: No
SDC:: Yes

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:: Health Outcomes

Pharmas:: Epic Science
Grants:: U10CA180821, U10CA180882, UG1CA189823

Corr. Author:
Authors:: Atish D. Choudhury Glenn Heller Melissa A. Reimers Andrew Laccetti Fabrice Smieliauskas Praful Ravi Katharine Dooley Gina L. Mazza Benjamin Gartrell Preston Steen Kayla Kroll Shiva Baghaie Archana Ajmera Thomas J. Smith Himisha Beltran Ronald Chen Rana R. McKay Matthew D. Galsky Jonathan E. Rosenberg Michael Morris

Networks:: CA249, KANSAS, LAPS-MA036, LAPS-MD017, LAPS-MO011, LAPS-NY016, MI020, MONTEFIORE, NY021, SANFORD

Study: Alliance-A032101
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords: